The Clinical Significance and Prognostic Value of ALDH1 Expression in
Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis

Dong      Li; Yu      Cao; Cheng-Wen      Luo; Li-ping      Zhang; Ying-Bo      Zou

doi:10.2174/0115748928265992230925053308

Abstract

Background: The results of the association between aldehyde dehydrogenase 1 (ALDH1) expression and prognosis of non-small cell lung cancer (NSCLC) are contradictory. We conducted this meta-analysis to investigate the clinical significance and prognostic value of ALDH1 in NSCLC.

Methods: The databases PubMed, Web of Science, EMBASE, the Cochrane Library, Wanfang, and CNKI were systematically queried to identify eligible studies. The retrieval time was from database establishment to August 2023. We evaluated the correlation between ALDH1 expression and clinical features of NSCLC by employing odds ratios (ORs) and 95% confidence intervals (95% CIs). In addition, we used hazard ratios (HRs) and 95% CIs to evaluate the role of ALDH1 expression in the prognosis of NSCLC.

Results: Our study included 21 literatures involving 2721 patients. The expression of ALDH1 in NSCLC was higher than that in normal tissues (OR = 6.04, 95% CI: 1.25-29.27, P = 0.026). The expression of ALDH1 was related to TNM stage (OR = 1.81, 95% CI: 1.06-3.09, P = 0.029), tumor grade (OR = 0.29, 95% CI: 0.17-0.48, P < 0.0001), lymph node metastasis (OR = 2.60, 95% CI: 1.52-4.45, P = 0001) and histological subtype (OR = 0.67, 95% CI: 0.52-0.86, P = 0.002). In patients with NSCLC, we found that the over-expression of ALDH1 was significantly associated with poor overall survival (OS) (HR = 1.44, 95% CI: 1.15-1.81, P = 0.002) and disease-free survival (DFS) (HR = 1.74, 95% CI: 1.45-2.10, P < 0.0001).

Conclusion: The expression of ALDH1 is closely associated with the clinicopathologic characteristics and prognosis of NSCLC. ALDH1 may serve as a valuable clinical assessment tool and prognostic predictor in NSCLC.

Keywords: Non-small cell lung cancer, aldehyde dehydrogenase 1, meta-analysis, prognostic, clinical significance, clinico pathological.

« Previous Next »

[1]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021; 71(3): 209-49.
 [http://dx.doi.org/10.3322/caac.21660] [PMID:  33538338]

[2]
Wang Y, Dong L, Zhong H, et al. Extracellular Vesicles (EVs) from lung adenocarcinoma cells promote human umbilical vein endothelial cell (HUVEC) angiogenesis through yes kinase-associated protein (YAP) transport. Int J Biol Sci  2019; 15(10): 2110-8.
 [http://dx.doi.org/10.7150/ijbs.31605] [PMID:  31592232]

[3]
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin  2019; 69(5): 363-85.
 [http://dx.doi.org/10.3322/caac.21565] [PMID:  31184787]

[4]
He L, Huang Y, Chen X, et al. Development and validation of an immune-based prognostic risk score for patients with resected non-small cell lung cancer. Front Immunol  2022; 13: 835630.
 [http://dx.doi.org/10.3389/fimmu.2022.835630] [PMID:  35401554]

[5]
Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol  2014; 25(8): 1462-74.
 [http://dx.doi.org/10.1093/annonc/mdu089] [PMID:  24562446]

[6]
Tsochantaridis I, Roupas A, Mohlin S, Pappa A, Voulgaridou GP. The concept of cancer stem cells: Elaborating on ALDH1B1 as an emerging marker of cancer progression. Life  2023; 13(1): 197.
 [http://dx.doi.org/10.3390/life13010197] [PMID:  36676146]

[7]
Chulpanova DS, Rizvanov AA, Solovyeva VV. The role of cancer stem cells and their extracellular vesicles in the modulation of the antitumor immunity. Int J Mol Sci  2022; 24(1): 395.
 [http://dx.doi.org/10.3390/ijms24010395] [PMID:  36613838]

[8]
Wang L, Wang L, Yu Y, et al. Aldehyde dehydrogenase 1 in gastric cancer. J Oncol  2022; 2022: 1-5.
 [http://dx.doi.org/10.1155/2022/5734549] [PMID:  35310914]

[9]
Vassalli G. Aldehyde dehydrogenases: Not just markers, but functional regulators of stem cells. Stem Cells Int  2019; 2019: 1-15.
 [http://dx.doi.org/10.1155/2019/3904645] [PMID:  30733805]

[10]
Han S, Huang T, Wu X, et al. Prognostic value of ALDH1 and Nestin in advanced cancer: A systematic meta-analysis with trial sequential analysis. Ther Adv Med Oncol  2019; 11.
 [http://dx.doi.org/10.1177/1758835919830831] [PMID:  30833990]

[11]
Zhou C, Sun B. The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: A meta-analysis. Oral Oncol  2014; 50(12): 1144-8.
 [http://dx.doi.org/10.1016/j.oraloncology.2014.08.018] [PMID:  25264224]

[12]
Zhao W, Zang C, Zhang T, et al. Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: A meta-analysis. OncoTargets Ther  2018; 11: 1821-31.
 [http://dx.doi.org/10.2147/OTT.S160207] [PMID:  29662319]

[13]
Chen J, Xia Q, Jiang B, et al. Prognostic value of cancer stem cell marker aldh1 expression in colorectal cancer: A systematic review and meta-analysis. PLoS One  2015; 10(12): e0145164.
 [http://dx.doi.org/10.1371/journal.pone.0145164] [PMID:  26682730]

[14]
Zheng Y, Wang L, Yin L, et al. Lung cancer stem cell markers as therapeutic targets: An update on signaling pathways and therapies. Front Oncol  2022; 12: 873994.
 [http://dx.doi.org/10.3389/fonc.2022.873994] [PMID:  35719973]

[15]
Merchant AA, Matsui W. Targeting Hedgehog--a cancer stem cell pathway. Clin Cancer Res  2010; 16(12): 3130-40.
 [http://dx.doi.org/10.1158/1078-0432.CCR-09-2846] [PMID:  20530699]

[16]
Alamgeer M, Ganju V, Szczepny A, et al. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax  2013; 68(12): 1095-104.
 [http://dx.doi.org/10.1136/thoraxjnl-2012-203021] [PMID:  23878161]

[17]
Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res  2009; 7(3): 330-8.
 [http://dx.doi.org/10.1158/1541-7786.MCR-08-0393] [PMID:  19276181]

[18]
Wang Q, Lin C. Expression of ALDH1 and AQP-5 proteins in NSCLC tissues and their relationship with clinical pathological parameters and prognosis of patients. Hebei Medical Journal  2021; 43(4): 548-51.
 [http://dx.doi.org/10.3969/j.issn.1002-7386.2021.04.015]

[19]
Yamashita N, So T, Miyata T, et al. Triple-negative expression (ALDH1A1-/CD133-/mutant p53-) cases in lung adenocarcinoma had a good prognosis. Sci Rep  2022; 12(1): 1473.
 [http://dx.doi.org/10.1038/s41598-022-05176-0] [PMID:  35087112]

[20]
Zhou L, Yu L, Zhu B, et al. Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer. BMC Cancer  2016; 16(1): 876.
 [http://dx.doi.org/10.1186/s12885-016-2903-z] [PMID:  27832750]

[21]
Koh YW, Han JH, Haam S, Jung J. ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: A study based on immunohistochemistry and mRNA expression data. J Cancer Res Clin Oncol  2019; 145(6): 1427-36.
 [http://dx.doi.org/10.1007/s00432-019-02906-2] [PMID:  30923946]

[22]
Miyata T, Oyama T, Yoshimatsu T, et al. The clinical significance of cancer stem cell markers ALDH1A1 and CD133 in lung adenocarcinoma. Anticancer Res  2017; 37(5): 2541-7.
 [http://dx.doi.org/10.21873/anticanres.11597] [PMID:  28476825]

[23]
Xue J, Zhao Y, Zou Q, Liang F, Lin F. The clinical and prognostic impact of aldehyde dehydrogenase 1 in non-small cell lung cancer: A meta-analysis. Transl Cancer Res  2020; 9(3): 1914-25.
 [http://dx.doi.org/10.21037/tcr.2020.02.09] [PMID:  35117538]

[24]
Wei D, Peng JJ, Gao H, Zhang T, Tan Y, Hu YH. ALDH1 expression and the prognosis of lung cancer: A systematic review and meta-analysis. Heart Lung Circ  2015; 24(8): 780-8.
 [http://dx.doi.org/10.1016/j.hlc.2015.03.021] [PMID:  25921687]

[25]
Huo W, Du M, Pan X, Zhu X, Li Z. Prognostic value of ALDH1 expression in lung cancer: A meta-analysis. Int J Clin Exp Med  2015; 8(2): 2045-51.
 [PMID:  25932135]

[26]
Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med  1998; 17(24): 2815-34.
 [http://dx.doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8] [PMID:  9921604]

[27]
Chi T, Wu S. Expression of the aldehyde dehydrogenase 1 and KAI1 in non-small cell lung cancer and its clinicopathological significance. J Bengbu Med Coll  2016; 41(9): 1138-41.
 [http://dx.doi.org/10.13898/j.cnki.issn.1000-2200.2016.09.006]

[28]
Cortes-Dericks L, Galetta D, Spaggiari L, Schmid RA, Karoubi G. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Eur J Cardiothorac Surg  2012; 41(6): e173. (e181)
 [http://dx.doi.org/10.1093/ejcts/ezs170]

[29]
Gao F, Zhou B, Xu JC, et al. The role of LGR5 and ALDH1A1 in non-small cell lung cancer: Cancer progression and prognosis. Biochem Biophys Res Commun  2015; 462(2): 91-8.
 [http://dx.doi.org/10.1016/j.bbrc.2015.04.029] [PMID:  25881507]

[30]
Hu K. The Expression and significance of ALDH1 and ABCG2 in Non-small-cell lung cancer. Bengbu Medical College 2013.

[31]
Huang H, Zhang J, Qiu X. Expression and significance of acetaldehyde dehydrogenase 1 in non-small cell lung cancer. Shandong Yiyao  2011; 51(49): 41-2.
 [http://dx.doi.org/10.3969/j.issn.1002-266X.2011.49.026]

[32]
Li Q. Expressin and cilnical significance of Setm Cell Marker CD133, CD34 and ALDHA1 in Lung Cancer. Qingdao University 2012.

[33]
Li X, Wan L, Geng J, Wu CL, Bai X. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol  2012; 7(8): 1235-45.
 [http://dx.doi.org/10.1097/JTO.0b013e318257cc6d]

[34]
Okudela K, Woo T, Mitsui H, et al. Downregulation of ALDH1A1 expression in non-small cell lung carcinomas--its clinicopathologic and biological significance. Int J Clin Exp Pathol  2013; 6(1): 1-12.
 [PMID:  23236537]

[35]
Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma-their prognostic significance. Pathol Int  2012; 62(12): 792-801.
 [http://dx.doi.org/10.1111/pin.12019] [PMID:  23252868]

[36]
Park E, Park SY, Sun PL, et al. Prognostic significance of stem cell-related marker expression and its correlation with histologic subtypes in lung adenocarcinoma. Oncotarget  2106; 7(27): 42502-12.
 [http://dx.doi.org/10.18632/oncotarget.9894] [PMID: 27285762]

[37]
Shien K, Toyooka S, Ichimura K, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer  2012; 77(1): 162-7.
 [http://dx.doi.org/10.1016/j.lungcan.2012.02.006] [PMID:  22387005]

[38]
Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res  2010; 70(23): 9937-48.
 [http://dx.doi.org/10.1158/0008-5472.CAN-10-0881] [PMID:  21118965]

[39]
Zenke Y, Ishii G, Ohe Y, et al. Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: Identification of prognostic microenvironmental factors after chemoradiation. Pathol Int  2013; 63(12): 599-606.
 [http://dx.doi.org/10.1111/pin.12122] [PMID:  24422956]

[40]
Zhuo Y, Liang D. Study on ALDH1 as the functional marker of lung cancer stem cells. Modern Journal of Integrated Traditional Chinese and Western Medicine  2015; 24(33): 3652-4.
 [http://dx.doi.org/10.3969/j.issn.1008-8849.2015.33.001]

[41]
Blomqvist M, Koskinen I, Löyttyniemi E, Mirtti T, Boström PJ, Taimen P. Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. Sci Rep  2021; 11(1): 13684.
 [http://dx.doi.org/10.1038/s41598-021-93245-1] [PMID:  34211078]

[42]
Ruscito I, Darb-Esfahani S, Kulbe H, et al. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecol Oncol  2018; 150(1): 151-7.
 [http://dx.doi.org/10.1016/j.ygyno.2018.05.006] [PMID:  29753392]

[43]
Wei Y, Li Y, Chen Y, et al. ALDH1: A potential therapeutic target for cancer stem cells in solid tumors. Front Oncol  2022; 12: 1026278.
 [http://dx.doi.org/10.3389/fonc.2022.1026278] [PMID:  36387165]

[44]
Lei HM, Zhang KR, Wang CH, et al. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. Theranostics  2019; 9(24): 7122-39.
 [http://dx.doi.org/10.7150/thno.35729] [PMID:  31695757]

[45]
Li Y, Wang B, Gui S, Ji J. Multiple copies in T-Cell Malignancy 1 (MCT-1) promotes the stemness of non-small cell lung cancer cells via activating interleukin-6 (IL-6) signaling through suppressing MiR-34a expression. Med Sci Monit  2019; 25: 10198-204.
 [http://dx.doi.org/10.12659/MSM.919690] [PMID:  31891569]

[46]
Jin L, Wu Z, Wang Y, Zhao X. Cryptotanshinone attenuates the stemness of non-small cell lung cancer cells via promoting TAZ translocation from nuclear to cytoplasm. Chin Med  2020; 15(1): 66.
 [http://dx.doi.org/10.1186/s13020-020-00348-4] [PMID:  32612672]

[47]
Liu M, Wu H, Xu C. Targeting cancer stem cell pathways for lung cancer therapy. Curr Opin Oncol  2023; 35(1): 78-85.
 [http://dx.doi.org/10.1097/CCO.0000000000000912] [PMID:  36475460]

[48]
MacDonagh L, Santiago RM, Gray SG, et al. Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. Transl Oncol  2021; 14(4): 101025.
 [http://dx.doi.org/10.1016/j.tranon.2021.101025] [PMID:  33550205]

Rights & Permissions Print Cite

Article Metrics

10

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115748928265992230925053308	Print ISSN 1574-8928
Publisher Name Bentham Science Publisher	Online ISSN 2212-3970

Recent Patents on Anti-Cancer Drug Discovery

The Clinical Significance and Prognostic Value of ALDH1 Expression in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis

Abstract

Related Journals

Related Books

Related Articles